Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.37 |
| ▸ | NMT1 | P30419 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608577 | 0.80 | ALDH1A1 (0.36) | EHMT2EHMT1NMT1JAK2JAK1 | |
| SCHEMBL24074322 | 0.76 | JAK2 (0.46) | JAK2JAK1JAK3NSD2ROCK2 | |
| SCHEMBL6208888 | 0.70 | NMT1 (0.45) | EHMT2EHMT1NMT1SLC2A1NSD2 | |
| SCHEMBL4609021 | 0.70 | MAP4K4 (0.41) | ROCK2 | |
| SCHEMBL13743574 | 0.69 | CCR4 (0.44) | EHMT2ROCK2HTR2C | |
| SCHEMBL3565009 | 0.65 | CTSL (0.40) | JAK2JAK1JAK3MCHR1ALDH1A1 | |
| SCHEMBL14384741 | 0.63 | — | — | |
| SCHEMBL13178388 | 0.63 | — | — | |
| SCHEMBL172592 | 0.62 | — | — | |
| SCHEMBL81996 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261918-A1 | Silicon Compounds and Their Use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1824863-B1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2008-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261918-A1 | Silicon Compounds and Their Use | SOST, SIK2, SCLY | EHMT2 1575/4885EHMT1 1567/4885NMT1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.